Cannabis Use Disorder May Up Risk of Benign Salivary Gland Tumors
MONDAY, July 21, 2025 -- Cannabis use disorder (CUD) is associated with increased risk of benign salivary gland tumors, according to a research letter published online July 17 in JAMA Otolaryngology-Head & Neck Surgery.
Tyler J. Gallagher, M.D., M.P.H., from the Keck School of Medicine at the University of Southern California in Los Angeles, and colleagues conducted a retrospective cohort study using deidentified data from the TriNetX U.S. Collaborative Network to examine the association between cannabis use and benign salivary gland tumors. Two cohorts of adults age 18 years or older were created: one had a diagnosis of cannabis-related disorder and the other had no cannabis-related disorder diagnosis between Jan. 24, 2005, and Jan. 24, 2025.
The researchers found that the incidence of any benign major salivary gland tumor was higher in the group with CUD (183,818 individuals) than the group without CUD (6,248,964 individuals) (0.08 versus 0.02 percent). The group with versus without CUD also had higher incidence of benign parotid salivary gland tumors (0.05 versus 0.01 percent). After propensity score matching, the relative risk of any benign major salivary gland tumor was higher among those with versus without CUD at all time points (relative risks, 5.18, 4.32, and 5.00 at any time, zero to less than five years, and at five or more years, respectively) after CUD diagnosis or outpatient hospital visit. Elevated relative risk of a benign parotid salivary gland tumor was also seen (relative risks, 5.16, 4.92, and 3.90 for any time, zero to less than five years, and five or more years, respectively).
"The elevated relative risk of benign parotid tumors and the persistent association over time highlight potential site-specific outcomes of cannabis use," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
2000 to 2023 Saw Rise in Pediatric Exposure to Medications, Supplements
MONDAY, Sept. 8, 2025 -- From 2000 to 2023, the rate of exposure to medications, dietary supplements, and psychoactive substances increased among children aged 6 to 12 years...
59.0 Percent of Overdose Deaths Involved Stimulants in 2021 to 2024
TUESDAY, Sept. 2, 2025 -- From 2021 to 2024, 59.0 percent of overdose deaths involved stimulants, according to research published in the Aug. 28 issue of the U.S. Centers for...
Unfavorable Mental Health Outcomes Reported With THC Product Use
TUESDAY, Aug. 26, 2025 -- High-concentration delta-9-tetrahydrocannabinol (THC) cannabis products are associated with unfavorable mental health outcomes, according to a review...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.